Results 21 to 30 of about 59,116 (263)
Changes in the Gut Microbiota May Affect the Clinical Efficacy of Oral Anticoagulants
Frontiers in Pharmacology, 2022 The mechanism underlying large individual differences in the response to oral anticoagulants has not been fully clarified, and the influence of the intestinal microbiome on exogenous drug metabolism has gradually become an area of increased research ...
Wenjun Chen +13 more
doaj +1 more source
Atrial Fibrillation, Oral Anticoagulants, and Concomitant Active Cancer: Benefits and Risks
TH Open, 2021 Aim To determine to what extent active cancer influences the benefit–risk relationship among patients with atrial fibrillation receiving oral anticoagulants for stroke prevention.
Adriano Atterman +3 more
doaj +1 more source
Безопасность и риск фармакотерапии, 2019 New oral anticoagulants are effective for the prevention of thromboembolic complications in patients with atrial fibrillation, or after orthopedic surgery.
A. P. Pereverzev +3 more
doaj +1 more source
Российский кардиологический журнал, 2019 Patients with atrial fibrillation have a high risk of developing stroke and death, which requires constant anticoagulant support. In this regard, the physician faces the difficult task of selecting the appropriate oral anticoagulant for patient with ...
N. N. Kryukov +3 more
doaj +1 more source
Oral anticoagulants: Optimizing venous thromboembolism management
Journal of Applied Hematology, 2019 A decade ago, oral anticoagulants were limited to Vitamin K antagonists, i.e., warfarin. Since 2010, the US Food and Drug Administration has approved several non-Vitamin K oral anticoagulants: dabigatran is a direct thrombin inhibitor, while apixaban ...
Fahad A S. Aleidan
doaj +1 more source
Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction
Рациональная фармакотерапия в кардиологии, 2021 Atrial fibrillation and renal dysfunction often coexist, each disorder may predispose to the other and contribute to worsening prognosis. Both atrial fibrillation and chronic kidney disease are associated with increased risk of stroke and thromboembolic ...
Z. D. Kobalava +2 more
doaj +1 more source
Canadian Medical Association Journal, 2012 These medications are approved for the prevention of venous thromboembolism after hip or knee replacement and the prevention of stroke in patients with nonvalvular atrial fibrillation. Rivaroxaban is also approved for the treatment of deep vein thrombosis in patients without symptomatic ...
Dongmei, Sun, Alejandro, Lazo-Langner
openaire +2 more sources
Consequences of oral antithrombotic use in patients with chronic kidney disease
Clinical and Translational Science, 2021 We assessed the risks of bleeding, acute kidney injury (AKI), and kidney failure associated with the prescription of antithrombotic agents (oral anticoagulants and/or antiplatelet agents) in patients with moderate‐to‐advanced chronic kidney disease (CKD).
Solène M. Laville +14 more
doaj +1 more source
Development of oral anticoagulants [PDF]
British Journal of Clinical Pharmacology, 2007 Warfarin has been the drug of choice for the prophylaxis and treatment of arterial and venous thrombotic disorders for over half a century [1]. It is the only oral anticoagulant currently approved for use in the US. Warfarin, a vitamin K antagonist, inhibits four vitamin K-dependent coagulation factors including prothrombin (factor II) and factors VII,
openaire +2 more sources
Oral anticoagulants in the elderly [PDF]
British Journal of Haematology, 2003 Summary. Over a 1‐year period, 34 998 prothrombin time tests were performed on 2379 patients aged 40–89 years with a recommended target International Normalized Ratio (INR) value of 2·5. At least one INR value of ≥ 5 was found in 507/2379 patients (21·3%).
Paul, Froom, Ehud, Miron, Mira, Barak
openaire +2 more sources